Dosage forms comprising a plasma kallikrein inhibitor
US11234939B2 · kind B2 · utility
0Cited by
11References
53Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 28, 2018 |
| Grant date | Feb 1, 2022 |
| Priority date | — |
| Expiry date | Jan 26, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to oral solid dosage forms comprising a plasma kallikrein inhibitor, in particular a solid form (Form 1) of the compound of Formula A. Also provided are methods of preparing oral solid dosage forms comprising the compound of Formula A using Form 1 of the compound of Formula A.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.